Lagos – The Managing Director, Greenlife Pharmaceuticals Limited, Dr Obiora Chukwuka, says his company will distribute to the Nigerian market a new herbal drug, `Manix`, which would cure Erectile Dysfunction (ED) among men.
Chukwuka said that the drug was manufactured by an Indian multinational, the Workhardt Limited.
The Managing Director, who made this known in Lagos on Saturday at the official handover of the product, said his company was the sole marketer of the product in Nigeria.
He explained that the drug would naturally treat infertility by regenerating damaged sex cells in the body.
“This is a scientifically proven herbal drug, which is basically used in the treatment of ED.
“It is also said to improve sperm count, increase semen volume, sperm motility in oligospermic males, libido, and sexual performance, among others.”
Chukwuka said the main cause of ED was progressing age, adding that a recent study in Nigeria showed that 57 per cent of men over the age of 35 had reported cases.
The Managing Director said the company decided to market Manix because it was the only scientifically tested herbal medication that has proven results for African men.
“Manix herbal capsules taken twice daily over 40 days increases testosterone by 26 per cent in African men. When taken for 90 days, the testosterone level increases by 85 per cent.
“The results are increase in sexual arousal and pleasure, penile rigidity for duration of erection leading to longer lasting and more satisfying sex.”
The Vice President, Wockhardt Limited, Mr Vithal Dhamankar, expressed appreciation over its partnership with Greenlife Pharmaceuticals, describing it as a dream come true.
Dhamankar, however, decried the level of infertility across the world and expressed the regret that most times, women bore the brunt of the situation as they were mostly blamed.
Mr Hemanshu Katira, the Product Development Manager, explained that infertility had become a global problem, adding that 50 per cent of infertility was of unknown causes.
Katira said the manufacturing of Manix was a holistic approach to address the problem of infertility, adding that already scientific studies had been conducted both in Nigeria and India to prove its efficacy.
Mr Kehinde Adegoke, a Clinical Laboratory Scientist, Lagos University Teaching Hospital (LUTH), who led the clinical trial of the drug, said that Manix increases semen volume and improves sperm motility.
“It increases the semen volume by 41 per cent, improves the sperm motility by 124 per cent and increases the sperm count by nearly four times over a period of 90 days.” (NAN)